Therapeutic Solutions files patent for stem cell-based cancer vaccine

By The Science Advisory Board staff writers

May 24, 2021 -- Therapeutic Solutions International has filed a patent for data that show a positive combined effect between its tumor blood vessel killing vaccine, StemVacs-V inducible pluripotent stem cell (iPSC), and particular immunological adjuvants.

StemVacs-V iPSC "is a cellular product generated from an inducible pluripotent stem cell (iPSC) which is differentiated into cells that resemble blood vessels which feed the tumor," the company said. The vaccine expresses the alpha1,3-galactosyltransferase gene, resulting in the potent expression of alpha Gal, a powerful immune stimulating molecule.

Therapeutic Solutions also plans to send the data to the U.S. Food and Drug Administration as part of an investigational new drug application.

Therapeutic Solutions advances its COVID-19 stem cell-based therapy
Therapeutic Solutions International announced new data and a patent filing demonstrating that lithium carbonate augments the scar-inhibiting activity...
Therapeutic Solutions to use immunotherapy for COVID-19
Therapeutic Solutions plans to develop its clinical stage cancer immunotherapy treatment StemVacs for treatment of COVID-19 patients.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter